3,560 material Form 8-K filings that 2,489 companies we cover made with the SEC in October 2026, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). 2,508 of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
Liquidia and its subsidiary Liquidia Technologies signed a settlement agreement with United Therapeutics on October 13, 2026, resolving all pending litigation between the companies. Liquidia will keep marketing YUTREPIA for pulmonary arterial hypertension but must remove the PH-ILD indication from the label and stop promoting it for that use, and it must make payments totaling a stated net $380.7 million in 2026 and 2027.
Net payment to United Therapeutics of $175.0 million due within 30 business days, plus $145.4 million in two $72.7 million installments due January 31, 2027 and April 30, 2027
Separate settlements with Sandoz, Henderson and PBM total about $60.3 million; the PBM agreement is with a related party that is controlled by a director, and the board's disinterested members approved it
Lender consent for a letter of credit tied to the settlement raised the minimum cash covenant under the revenue interest financing agreement from $15.0 million to $45.0 million
Preliminary, unaudited third-quarter 2026 YUTREPIA net product sales were $222.7 million, and cash and cash equivalents were $396.1 million as of September 30, 2026
On October 13, 2026, Biomea Fusion reported topline Phase 1 GLP-131 results for BMF-650, its investigational oral GLP-1 receptor agonist. In Cohorts 1-4, mean Day 29 weight reduction ranged from 1.5% to 3.2% versus 0.1% for pooled placebo, and the company reported no severe or serious adverse events among active-dose participants, but the results are preliminary, the sample sizes are small, and the company says longer-term toxicology studies are still needed before further development, which may include a partnership.
Cohorts 1-4 (outpatient): mean Day 29 weight reduction of 1.5% to 3.2% versus 0.1% for pooled placebo.
Cohort 5 (under confinement, 200 mg then 400 mg): 6.1% (6.2 kg) mean weight reduction at Day 29; the company says it should be interpreted separately because confinement appeared to affect eating behavior.
No severe or serious TEAEs, TEAE-related dose modifications, or TEAE-related discontinuations across the 40 active-dose MAD participants; nausea occurred in 17.5% and vomiting in 7.5% across active cohorts.
Longer-term toxicology studies are required; the company is positioning BMF-650 for a strategic partnership, which could include licensing, while its primary focus remains icovamenib.
Sadot Group and VisionWave Holdings terminated the joint venture agreement for CMJV LLC, which was set up to lend to Israeli advanced-composites maker C.M. Composite Materials, effective October 12, 2026. CM told the company on or about October 8, 2026 that it could not produce the financial statements the agreement required, so no funding took place. The company has no further funding obligation and no break fee, and it will receive 500,000 VisionWave common shares, while VisionWave keeps the 250,000 entry premium shares it already held.
Termination Agreement dated October 12, 2026 ends the JV Agreement dated September 30, 2026, which had committed the company to contribute $7,814,323 in cash over twelve months.
The company had funded none of the commitment, and it paid no early termination penalty or break fee.
The company's 7,814,323 CMJV membership units were cancelled for no consideration, and it no longer holds any interest in CMJV or CM.
VisionWave agreed to issue the company 500,000 shares of its common stock, and the company expects them to be restricted securities.
On October 12, 2026, VisionWave agreed with Sadot Group and others to terminate the September 30 joint venture, after CM said it could not produce the financial statements the agreement required. Sadot's funding commitment of up to $7,814,323 was extinguished without any amount being funded, and no termination penalty is payable. VisionWave keeps 250,000 Sadot shares and will issue 500,000 of its own common shares to Sadot, while it also takes on indemnification obligations to Sadot.
Letter Agreement dated October 12, 2026 terminated the JV Agreement signed September 30, 2026 with Sadot Group Inc. and CMJV LLC
Sadot's Capital Commitment of up to $7,814,323 was terminated and none of it was funded; no early termination penalty or break fee is payable
VisionWave will issue 500,000 shares of common stock to Sadot within three business days and retains 250,000 Sadot Entry Premium Shares
VisionWave, VisionWave Israel and CMJV jointly and severally agreed to indemnify Sadot against losses tied to the CM Rights and related matters
Dot Ai (CID HoldCo, Inc.) closed its acquisition of Envoy Technologies, Inc. on October 9, 2026, making Envoy a wholly owned subsidiary. The deal was paid in Dot Ai common stock and Series C Preferred Stock, valued at about $65.0 million at a $6.00 reference price, and it is expected to leave BladeRanger holding a majority of Dot Ai's common stock on an as-converted basis once conversions are completed, which would dilute existing shareholders. The company believes it now meets Nasdaq's $2.5 million stockholders' equity requirement, but its continued listing remains subject to the Nasdaq Hearings Panel's confirmation.
Closed October 9, 2026; BladeRanger received 233,543 common shares and 8,433,123 Series C Preferred Shares at closing
Blink Charging holds a $12,500,000 Envoy convertible note that will convert into 2,166,667 common shares upon stockholder approval and an effective Form S-1 registration statement
Dot Ai believes its stockholders' equity meets the $2.5 million Nasdaq minimum; the Nasdaq Hearings Panel must confirm
Parties agreed to use reasonable best efforts to obtain stockholder approval by January 31, 2027
Nasdaq's Hearings Panel decided on October 7, 2026, that CN Healthy Food Tech Group is in compliance and may remain listed, subject to conditions. The panel found the company failed to give Nasdaq and investors accurate information about its China Securities Regulatory Commission application, though it said the omission did not relate to finances or business operations.
Panel decision dated October 7, 2026; company may remain listed on Nasdaq
Company must keep remedial measures for three years from the panel decision date
One-year Discretionary Panel Monitor: any listing standard failure leads to a Staff Delisting Determination without a cure period
Company does not intend to seek Listing Council review; the council may still review on its own within 45 days
MasterCraft filed unaudited pro forma combined results for the fiscal year ended June 30, 2026, showing how its May 15, 2026 acquisition of Marine Products Corporation would have looked had it closed July 1, 2025. The pro forma loss from continuing operations is $10.0 million, or $0.40 per share, compared with MasterCraft's historical loss of $1.6 million, or $0.09 per share. The filing is supplemental and does not report actual combined results.
Pro forma net sales of $565.8 million, versus MasterCraft historical net sales of $348.9 million
Pro forma loss from continuing operations of $10.0 million, or $0.40 per share, on 25,251,021 weighted average shares
Total merger consideration of $284.2 million: $199.4 million in stock (8,088,171 shares) and $84.8 million in cash
Preliminary purchase price allocation; the company says final amounts may differ materially and that the figures exclude synergies and integration costs
On September 30, 2026, Interactive Strength exchanged $7,685,090 of outstanding convertible note obligations for 768,509 shares of newly designated Series R Convertible Preferred Stock, and the notes were cancelled. On October 1, 2026, subsidiary Wattbike refinanced its working capital facility with up to £1,375,000 (about $1,825,200) of new term, invoice discounting and inventory financing, with lenders holding security over its assets. The Series R preferred ranks senior to common stock and is convertible into common, and the new loans include events of default that allow lenders to demand immediate repayment.
September 30, 2026: $7,685,090 of remainder notes exchanged for 768,509 Series R Preferred shares; company to reimburse holders $50,000 in legal fees
October 1, 2026: Wattbike prior facility repaid in full, with a £85,000 (about $112,800) exit fee and new financing of up to £1,375,000 (about $1,825,200)
Inventory loan facility of up to £750,000 (about $995,600) carries interest of 1.85% per month and is secured by a debenture over all Wattbike assets
Series R Preferred ranks senior to common stock; 1,619,907 common shares were outstanding as of September 30, 2026
Wheeler Real Estate Investment Trust entered into a Note Purchase Agreement on October 13, 2026, to issue promissory notes totaling up to $25 million in principal, with the initial note at $1 million. The notes carry 0.00% interest, mature 18 months after issuance, and require amortization payments that can be made in common stock, which could dilute existing shareholders, subject to stockholder approval and an effective registration statement.
Initial Note Investor purchase: $1,000,000 principal note; maximum aggregate principal of up to $25,000,000 across Notes.
Notes bear 0.00% interest and mature 18 months after issuance; amortization payment set at 0.4% of original principal per trading day, adjustable between 0.2% and 0.6%.
Amortization payments are paid in common stock at market value, or in cash if the price is below $0.25 per share or other listed conditions are not met.
Closing requires stockholder approval for issuance above 19.99% of outstanding common stock and an effective resale registration statement; purchase price is paid in Series D Preferred Stock at $25.00 liquidation preference.
SSR Mining agreed on October 13, 2026 to acquire all outstanding shares of Roxmore Resources through a British Columbia plan of arrangement, paying C$6.75 per share in cash. The company said the cash component is funded from its current balance sheet and estimated the fully diluted equity value at about $464 million, with enterprise value of $392 million, excluding the value of a new spin-off company. The deal adds Roxmore's Converse gold project in Nevada, six kilometers from SSR's Marigold mine, which the company says could add about 150,000 to 170,000 ounces of annual gold production with initial capital of $800 million to $900 million.
Cash consideration of C$6.75 per Roxmore common share; estimated fully diluted equity value of about $464 million and enterprise value of $392 million, excluding SpinCo
Closing requires approval by at least 66 2/3% of votes cast by Roxmore securityholders, and the Supreme Court of British Columbia; the company expects completion in Q4 2026
Either party may terminate if closing has not occurred by April 13, 2027; Roxmore would owe a C$18.0 million termination fee in certain circumstances
Roxmore securityholders with about 26.8% of shares have agreed to vote in favor; SSR Mining will hold a 14.99% stake in SpinCo, which will receive US$10.0 million in funding
Johnson & Johnson reported third-quarter 2026 sales up 5.9% to $25.4 billion, but net earnings fell 95.9% to $210 million after a one-time special charge for the proposed talc litigation resolution. Adjusted EPS fell 7.5% to $2.59, and the company raised its full-year 2026 adjusted EPS guidance midpoint to $11.10, which matters to shareholders because the higher outlook is offset by a large reported charge and lower adjusted profit.
Q3 2026 reported sales were $25,399 million, up 5.9% from $23,993 million; net earnings were $210 million versus $5,152 million, and diluted EPS was $0.09 versus $2.12.
Adjusted diluted EPS was $2.59 versus $2.80 a year earlier, down 7.5%.
Full-year 2026 adjusted EPS guidance midpoint rose to $11.10 from $11.04 in July 2026; estimated reported sales midpoint is $101.2 billion.
Other (income) expense, net was $5,780 million in the quarter, reflecting the talc litigation charge, the Firefly Bio acquisition and the Sail Biomedicines collaboration.
Mesa Laboratories approved a restructuring program that eliminates about 40 positions, mainly in its Clinical Genomics division, and exits its Hamburg, Germany facility when its lease expires in February 2027. The company expects a net annualized cost reduction of about $5.0 million after reinvestment, but says Clinical Genomics revenue will be lower as it narrows its focus to pharmacogenomics and oncology.
Estimated total pre-tax charges of $2.6 million to $3.4 million, mainly in the second half of fiscal year 2027
Expected related cash expenditures of $2.9 million to $3.7 million, substantially all over the next 12 months
Savings plan to reduce annualized operating costs by about $9.3 million, with about $4.3 million reinvested
Company will report second quarter fiscal year 2027 results and provide fiscal 2027 guidance on November 9, 2026
AllianceBernstein reported preliminary month-end assets under management of $900 billion at September 30, 2026, down from $919 billion at August 31, a 2% decline driven mainly by market depreciation and net outflows in the month. For the quarter ended September 30, 2026, preliminary firmwide net inflows totaled approximately $6.0 billion, so the monthly AUM decline sits alongside positive quarterly net flows.
Month-end AUM was $900 billion at September 30, 2026, versus $919 billion at August 31, 2026.
Institutional channel had net inflows, partly offset by net outflows in Retail and Private Wealth.
Preliminary firmwide net inflows for the quarter ended September 30, 2026 were approximately $6.0 billion.
Northern Oil and Gas (NOG) issued a preliminary third quarter 2026 operational update on October 12, 2026, reporting clean operations and an expected $250.0 million to $253.0 million in third quarter capital expenditures. The company also expects large derivative losses, with unrealized mark-to-market losses of $300 million to $320 million and realized hedge losses of $51 million to $52 million, and the figures remain subject to final closing procedures.
Expected third quarter unrealized mark-to-market losses on derivatives of $300 million to $320 million, with realized hedge losses of $51 million to $52 million.
Expected third quarter capital expenditures of $250.0 million to $253.0 million, excluding non-budgeted acquisitions; the company reiterated its 2026 capital guidance and expects spending toward the higher end of the range.
Repurchased 667,989 shares for $16.0 million in the third quarter at an average of $23.96 per share; about $227.2 million remains under the buyback program after a $150.0 million increase authorized in July 2026.
Declared a $0.45 quarterly cash dividend on August 4, 2026, payable October 30, 2026.
Xponential Fitness's board adopted a limited-duration stockholder rights plan that becomes exercisable if a person or group acquires 19.9% or more of Class A shares. The company said the plan aims to prevent a large accumulation of shares that could hurt trading, and that it will not block an acquisition but encourages bidders to negotiate with the board first. The board's strategic alternatives review, with Jefferies as financial advisor, remains ongoing.
Rights are issued to holders of record as of October 22, 2026, and expire October 11, 2027 unless redeemed earlier.
Rights become exercisable only if a person or group acquires 19.9% or more of outstanding shares; exercise price is $15.00 per Unit.
The company may redeem the rights for $0.001 per right before they become exercisable.
The filing says the strategic alternatives review led by independent directors remains ongoing, with Jefferies as financial advisor.
Occidental Petroleum said in an 8-K that its third quarter 2026 production is within guidance, despite temporary September curtailments at Gulf of America facilities caused by a third-party gas pipeline constraint and maintenance. The company also said crude oil collar settlements reduced operating cash flow before working capital by $94 million, and it provided preliminary Q3 price, volume and share count figures ahead of full results. The considerations are preliminary and not an earnings estimate, so shareholders will need the final third quarter report to gauge profit.
Total company Q3 2026 production is within Occidental's guidance range, including the Gulf of America downtime
Gulf of America net sales volumes were 110 Mboed and domestic lease operating cost was $8.54 per boe in the quarter
Crude oil collar settlements reduced Q3 operating cash flow before working capital by $94 million
Worldwide average realized oil price was $85.91 per barrel versus WTI at $85.79; average diluted shares were 1,012.8 million
ADC Therapeutics agreed on October 7, 2026 to sell equity in an $86.6 million private placement, with closing expected October 22, 2026. The company also amended its term loan, cutting principal to $50.0 million, and amended its HealthCare Royalty agreement, removing a $150 million change-of-control payment. The filing gives preliminary third-quarter ZYNLONTA net product revenue of about $21.0 million and cash of $189.2 million, and the new share sales and warrant repricing add dilution for existing shareholders.
Private placement of 12,911,347 common shares at $1.42 per share, plus pre-funded warrants for 48,088,653 shares, expected to close October 22, 2026
Term loan prepayment of $70.0 million leaves $50.0 million outstanding; minimum liquidity covenant eliminated and a $65.0 million ZYNLONTA sales covenant set for the quarter ending December 31, 2026
HCR amendment removes the $150 million change-of-control payment and lets the company buy out royalties for $525 million by December 31, 2029 or $750 million from January 1, 2030
Preliminary Q3 2026 ZYNLONTA net product revenue of about $21.0 million; cash and equivalents of $189.2 million as of September 30, 2026
Brent Saunders left his roles as Bausch + Lomb chief executive and board member, effective October 12, 2026, under a mutually agreed separation. Thomas J. Appio, the board chairman who also serves as CEO of parent Bausch Health, was named interim CEO. The company said it expects to raise its full-year 2026 adjusted EBITDA guidance excluding Acquired IPR&D, based on preliminary third-quarter results.
Saunders' separation agreement provides a $75.5 million lump-sum cash payment and up to $50,000 in attorneys' fees, subject to a release of claims.
All of Saunders' outstanding equity awards, vested or unvested, were forfeited and cancelled.
Appio serves as interim CEO while remaining CEO of Bausch Health, the company's controlling shareholder.
The company expects to raise full-year 2026 adjusted EBITDA guidance excluding Acquired IPR&D; details are due with third-quarter results on October 28.
SS Innovations International entered a Securities Purchase Agreement on October 9, 2026, issuing a secured convertible promissory note with a $21,025,000 principal amount for a $20,000,000 purchase price. The note bears 8.75% interest, matures 36 months after closing, and is secured by the company's intellectual property and most subsidiary assets, which could dilute existing shareholders through conversions.
Note issued October 9, 2026 with $21,025,000 principal for a $20,000,000 purchase price, including $1,000,000 original issue discount and $25,000 investor expenses
Interest at 8.75% per annum compounded daily; matures 36 months after the Closing Date
Investor may convert at 95% of Market Price beginning on the Effective Date; company reserved an initial 8,000,000 common shares for conversions
Note secured by company IP held by SSI IP Holdings and assets of the company and SS IP; Indian subsidiary SSI-India excluded from collateral
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.